Guidance on using infliximab biosimilars
The National Institute for Health and Care Excellence (NICE) has published a new resource that provides practical information and advice on the adoption of biosimilar versions of infliximab (Inflectra and Remsima). It is intended for use by both clinical and non-clinical staff considering the introduction of these biosimilar medicines into the NHS. The resource can be accessed via the NICE website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069103
Recommended from Pharmaceutical Press
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.£82.00Buy now